Key result
Fluorine-18 fluorodeoxyglucose PET/CT imaging provides high metabolic contrast that can aid in diagnosing tumour thrombosis when conventional imaging modalities are imprecise.
F-FDG PET/CT is a valuable imaging modality for differentiating malignant tumour thrombi from bland thrombi in oncologic patients.
May support FDG-PET/CT for ambiguous tumour thrombi in oncology; leaves open need for prospective validation.
Tumour thrombosis (TT) is a very rare but serious complication in oncologic patients. The presence of TT has a significant impact on tumour staging, treatment decisions and prognosis in many malignancies. Current diagnostic techniques show poor ability to differentiate between bland and malignant thrombi; tumour thrombi are also usually inaccessible for biopsies, making their diagnosis difficult. In recent times, fluorine-18 fluorodeoxyglucose PET/computed tomography (F-FDG PET/CT) has well established its role in oncological imaging because of the high metabolic contrast of F-FDG between malignant and normal tissue. Patients with tumour thrombi may benefit from F-FDG PET/CT imaging when TT cannot be diagnosed precisely by other conventional imaging modalities. Here we provide a pictorial review of a few common and unusual sites of tumour thrombus in different malignancies and their patterns of F-FDG uptake.
No takes yet. Share an insight, caveat, or question.
Aurangabadkar et al. (2013) conducted a review in Tumour thrombosis. Fluorine-18 fluorodeoxyglucose PET/CT was evaluated. Fluorine-18 fluorodeoxyglucose PET/CT imaging provides high metabolic contrast that can aid in diagnosing tumour thrombosis when conventional imaging modalities are imprecise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: